CAR-T

3 Biotech Stocks That Skyrocketed This Past Week
Motley Fool
Mon, 09/4/17 - 10:07 am
Abeona Therapeutics
EB-101
Sangamo BioSciences
SB-525
Juno Therapeutics
CAR-T
Takeda partners with Noile-Immune on next-gen CAR-T pipeline for solid tumors
Endpoints
Mon, 09/4/17 - 10:05 am
Takeda
Noile-Immune
CAR-T
solid tumors
Neurotoxicity kills a CAR-T rival pushed by J&J, MacroGenics in $700M deal
Endpoints
Fri, 09/1/17 - 11:31 pm
JNJ
CAR-T
Macrogenics
MGD011
Landmark approval won, Novartis' next test is scaling CAR-T manufacturing
BioPharma Dive
Fri, 09/1/17 - 11:24 am
Novartis
CAR-T
Kymriah
FDA
drug manufacturing
Profit on $475,000 Novartis cancer drug could be a while coming
Yahoo/Reuters
Fri, 09/1/17 - 11:15 am
Novartis
CAR-T
Kymriah
Why bluebird bio Inc Continued Its March Higher Again Today
Motley Fool
Thu, 08/31/17 - 10:13 pm
Bluebird Bio
bb2121
CAR-T
Novartis
Kymriah
Gilead Sciences
Kite Pharma
Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences
Motley Fool
Thu, 08/31/17 - 10:11 pm
Novartis
CAR-T
Kymriah
Gilead Sciences
Kite Pharma
M&A
A Cancer Doc Weighs In On CAR-T, Precision Medicine And Pricing Debates
Forbes
Thu, 08/31/17 - 09:17 am
CAR-T
precision medicine
drug pricing
Novartis
Kymriah
Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
Forbes
Wed, 08/30/17 - 11:53 pm
Novartis
CAR-T
drug pricing
FDA
acute lymphoblastic leukemia
Kymriah
Joe Jimenez
Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000
Xconomy
Wed, 08/30/17 - 11:48 pm
Novartis
FDA
CAR-T
drug pricing
Kymriah
acute lymphoblastic leukemia
Has Gilead Sciences' Big Bounce Begun With the Kite Pharma Buyout?
Motley Fool
Wed, 08/30/17 - 10:04 am
Gilead Sciences
CAR-T
Kite Pharma
M&A
How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight
Fierce Pharma
Tue, 08/29/17 - 09:07 pm
Gilead Sciences
Kite Pharma
CAR-T
drug pricing
M&A
Here's What Else Gilead Sciences Gets by Buying Kite Pharma
Motley Fool
Tue, 08/29/17 - 10:01 am
Gilead Sciences
Kite Pharma
M&A
CAR-T
TCR-targeted drugs
To Be More Than a Quick Splash, Gilead’s CAR-T Purchase Faces Hurdles
Xconomy
Tue, 08/29/17 - 01:12 pm
Gilead Sciences
Kite Pharma
M&A
CAR-T
5 Reasons The Gilead-Kite Acquisition Might Work
Seeking Alpha
Mon, 08/28/17 - 10:47 pm
Gilead Sciences
M&A
Kite Pharma
CAR-T
Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today
Motley Fool
Mon, 08/28/17 - 10:26 pm
Bluebird Bio
Juno Therapeutics
Gilead Sciences
Kite Pharma
CAR-T
M&A
Gilead agrees to buy Kite Pharma, leaping into CAR-T cancer therapy
Stat
Mon, 08/28/17 - 10:04 am
Gilead Sciences
Kite Pharma
CAR-T
M&A
axi-cel
New CAR-T drug for leukemia, while effective, is ‘going to cost a fortune’
Stat
Wed, 08/23/17 - 11:41 am
CAR-T
Novartis
drug pricing
CTL019
leukemia
Novartis CEO opens door to cancer patient demanding ‘fair’ CAR-T pricing
Fierce Pharma
Tue, 08/22/17 - 12:05 am
Novartis
Pharma CEOs
CAR-T
Joe Jimenez
drug pricing
Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study
Endpoints
Sat, 08/19/17 - 10:29 am
Medvir
hepatitis C
China
Ascletis
Cellectis
UCART123
CAR-T

Pages